1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
1
Active Trials
200 recruiting
5
Rare Diseases
across 15 areas
0
News (30d)
Quiet
Ashvattha Therapeutics is a company with 1 orphan drug designation across 5 rare diseases. Active clinical trials in 1 indication. 2 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Alzheimer disease | - | Des.TrialAppr. |
| Parkinson disease | - | Des.TrialAppr. |
| adrenoleukodystrophy | generation 4 hydroxyl-terminated polyamidoamine dendrimer containing an ethylene diamine (EDA) core, amidoamine repate units, and 64 hydroxyl end groups | Des.TrialAppr. |
| amyotrophic lateral sclerosis | - | Des.TrialAppr. |
| multiple sclerosis | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
35
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
2
affecting portfolio
0% of portfolio targets high unmet need diseases
35
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
2
affecting portfolio